Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tianhong Luo

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Clinical Therapeutics|January 31, 2025
Bioequivalence of Water-Soluble Progesterone Injection (GenSci070) in Healthy Chinese Postmenopausal Women VolunteersRong Song, Xue Wu, Liang Xin, et al.
ACR Open Rheumatology|November 7, 2025
Firsekibart as a Prophylactic Treatment for Acute Gout Flare in Participants Initiating Urate-Lowering Therapy: A Phase 2, Randomized, Open-Label, Multicenter, Active-Controlled TrialYiyun Yu, Yu Xue, Jiankang Hu, et al.
Experimental Animals|November 20, 2003
The rat model of type 2 diabetic mellitus and its glycometabolism charactersFanglin Zhang, Chuanzhong Ye, Guo Li, et al.
Frontiers in Endocrinology|August 1, 2022
PEGylated Recombinant Human Growth Hormone Jintrolong<sup>®</sup> Exhibits Good Long-Term Safety in Cynomolgus Monkeys and Human Pediatric Growth Hormone Deficiency PatientsWei Wu, Juan Zhou, Chuandong Wu, et al.
Journal of Human Genetics|May 16, 2006
The -822G/A polymorphism in the promoter region of the MAP4K5 gene is associated with reduced risk of type 2 diabetes in Chinese Hans from ShanghaiYanyun Gu, Tianhong Luo, Jian Yang, et al.
Rheumatology and Therapy|August 20, 2025
Efficacy and Safety of Firsekibart Compared to Etoricoxib for Gout Flares: A Phase 2, Multicenter, Open-label, Active-controlled, Randomized Non-inferiority TrialNing Kong, Yu Xue, Li Mao, et al.
Journal of Diabetes|June 22, 2019
Observational study evaluating the effectiveness of physician-targeted education for improving glycemic management of patients with type 2 diabetes (BEYOND II)Jianping Weng, Jiajun Zhao, Zhiguang Zhou, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Clinical Therapeutics|January 31, 2025
Bioequivalence of Water-Soluble Progesterone Injection (GenSci070) in Healthy Chinese Postmenopausal Women VolunteersRong Song, Xue Wu, Liang Xin, et al.
ACR Open Rheumatology|November 7, 2025
Firsekibart as a Prophylactic Treatment for Acute Gout Flare in Participants Initiating Urate-Lowering Therapy: A Phase 2, Randomized, Open-Label, Multicenter, Active-Controlled TrialYiyun Yu, Yu Xue, Jiankang Hu, et al.
Experimental Animals|November 20, 2003
The rat model of type 2 diabetic mellitus and its glycometabolism charactersFanglin Zhang, Chuanzhong Ye, Guo Li, et al.
Frontiers in Endocrinology|August 1, 2022
PEGylated Recombinant Human Growth Hormone Jintrolong<sup>®</sup> Exhibits Good Long-Term Safety in Cynomolgus Monkeys and Human Pediatric Growth Hormone Deficiency PatientsWei Wu, Juan Zhou, Chuandong Wu, et al.
Journal of Human Genetics|May 16, 2006
The -822G/A polymorphism in the promoter region of the MAP4K5 gene is associated with reduced risk of type 2 diabetes in Chinese Hans from ShanghaiYanyun Gu, Tianhong Luo, Jian Yang, et al.
Rheumatology and Therapy|August 20, 2025
Efficacy and Safety of Firsekibart Compared to Etoricoxib for Gout Flares: A Phase 2, Multicenter, Open-label, Active-controlled, Randomized Non-inferiority TrialNing Kong, Yu Xue, Li Mao, et al.
Journal of Diabetes|June 22, 2019
Observational study evaluating the effectiveness of physician-targeted education for improving glycemic management of patients with type 2 diabetes (BEYOND II)Jianping Weng, Jiajun Zhao, Zhiguang Zhou, et al.
Pageof 3